These analyses revealed no statistically significant interaction of BMI or hormone replacement therapy use on the relationship between PA level at enrollment or changes in PA level and risk of postmenopausal breast cancer overall, or by ER/PR status (data not shown). This evidence concerns the gene ESR1 and breast cancer.